Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 16;37(1):36.
doi: 10.1186/s43046-025-00296-w.

IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study

Moez Eid  1 , Dema Alset  2 , Nataliya Timoshkina  1 , Dmitriy Gvaldin  1 , Eduard Rostorguev  1 , Sergey Kavitskiy  1 , Inna Novikova  1
Affiliations

IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study

Moez Eid et al. J Egypt Natl Canc Inst. .

Abstract

Glioma is a devastating type of brain tumor with high malignancy, an extremely high mortality rate, and a recurrence risk. Molecular markers are known to have a major role in classification, prognosis, survival rate, and therapy determination for different glioma subtypes. The aim of this study was to investigate the association of gliomas' main genetic markers: isocitrate dehydrogenase (IDH) mutations and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status with the survival rate in Russian patients with glioblastoma and other glial tumors. According to histological subtype, included glioma patients were divided into two groups: glioblastoma (n = 90) and other gliomas (n = 40). IDH mutations were screened by high-resolution melting-curve analysis (HRM) followed by direct sequencing, and MGMT methylation was detected with pyrosequencing. Our data showed that IDH mutations are significantly more frequent among patients with other gliomas compared to glioblastoma patients (p < 0.001). Patients with mutated IDH gene have a significantly higher progression-free survival (PFS) and overall survival (OS) rates than those with wild-type genes. MGMT promoter methylation status was found to be significantly associated with PFS, but not OS. The presence of IDH mutation with a methylated MGMT promoter significantly increased patients' PFS and OS. To our knowledge, this is the first study to investigate the association of IDH and MGMT genetic biomarkers with glioma in the Russian population. Our findings could be used in future studies to improve glioma prognosis and classification and reach a personalized treatment protocols depending on multiple molecular biomarkers.

Keywords: IDH; MGMT; Glioblastoma; Glioma; Survival rate.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Study design and methods were approved by the National Ethics Committee. All participants (or their parent or legal guardian in the case of children under 16) provided willingly written informed consent for inclusion before they participated in the study. Consent for Publication: Written informed consent for publication was obtained from all participants (or from their parent or legal guardian in the case of children under 16). Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Aoki K, Natsume A. Overview of DNA methylation in adult diffuse gliomas. Brain Tumor Pathol. 2019;36(2):84–91. https://doi.org/10.1007/s10014-019-00339-w . - DOI - PubMed
    1. Bou Zerdan M, Atoui A, Hijazi A, Basbous L, Abou Zeidane R, Alame SM, Assi HI. Latest updates on cellular and molecular biomarkers of gliomas. Front Oncol. 2022;12:1030366. https://doi.org/10.3389/fonc.2022.1030366 . - DOI - PubMed - PMC
    1. Chai R, Li G, Liu Y, Zhang K, Zhao, Z, Wu F, Chang Y, Pang B, Li J, Li Y, Jiang T, & Wang Y. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med. 2021;18(1):272–282. https://doi.org/10.20892/j.issn.2095-3941.2020.0179
    1. Cheng HB, Yue W, Xie C, et al. IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis. Tumor Biol. 2013;34:3555–9. https://doi.org/10.1007/s13277-013-0934-5 . - DOI
    1. Cho U, Yang SH, Yoo C. Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience. J Int Med Res. 2021;49(6):3000605211019258. https://doi.org/10.1177/03000605211019258 . - DOI - PubMed

MeSH terms